Skip to content
Inciteful Med

Standard of Care Treatment: Surgery & Medical Therapies

Last updated:

Endoscopic transsphenoidal surgery is the primary first-line treatment for acromegaly, aiming to remove the pituitary tumor and normalize hormones. If surgery isn't fully effective, targeted medications like SRLs or Pegvisomant are used, with radiation therapy as a third-line option.

Key Takeaways

  • • Endoscopic transsphenoidal surgery is the primary and most efficient first-line treatment for acromegaly.
  • • If surgery does not fully normalize hormone levels, medical therapies like Somatostatin Receptor Ligands (SRLs) are the next step.
  • • Pegvisomant is a highly effective medication that blocks growth hormone from working, meaning doctors must monitor your IGF-1 levels instead of GH levels.
  • • Radiation therapy is typically reserved as a third-line option and can take several years to effectively lower hormone levels.

Managing acromegaly is often a journey that moves through several stages of care. While the goal is always to normalize your hormone levels and reduce the size of the tumor, the path to getting there is personalized based on how your body responds [1][2].

The First Line: Surgery

For the vast majority of patients, endoscopic transsphenoidal surgery is the primary and most efficient treatment [3].

  • The Procedure: A neurosurgeon uses a thin tube with a camera (endoscope) to reach the pituitary gland through the nose and sphenoid sinus [4][5]. This “minimally invasive” approach allows the surgeon to visualize and remove the tumor without making any external incisions [3][6].
  • Success Rates: Surgery results in biochemical remission (normal hormone levels) for about 69% to 74% of patients [7][8]. Smaller tumors (microadenomas) generally have higher success rates than larger, invasive ones (macroadenomas) [8][7].
  • Surgical Risks: While effective, this is brain surgery. Potential risks include a cerebrospinal fluid (CSF) leak, meningitis, or damage to the normal pituitary gland. Damage to the gland could cause permanent hormone deficiencies (such as diabetes insipidus, a condition affecting water balance) that require lifelong medication [4][6].

Second Line: Medical Therapies

If surgery is not possible, or if some tumor tissue remains and your hormones stay high, doctors turn to medications [3][2].

1. Somatostatin Receptor Ligands (SRLs)

These are the most common first-line medications after surgery [9]. They mimic a natural hormone called somatostatin, which tells your body to stop producing growth hormone [2].

  • First-Generation (Octreotide, Lanreotide): These are usually given as monthly long-acting injections [9]. They successfully normalize IGF-1 levels in 20% to 70% of patients [10].
  • Side Effects and Logistics: These medications commonly cause temporary gastrointestinal (GI) upset. They also carry a risk of forming gallstones (cholelithiasis), so you may need routine gallbladder ultrasounds [9]. Depending on the specific drug, injections may be given deep into the muscle by a nurse at a monthly clinic visit, or as a subcutaneous shot that you or a partner can learn to administer at home [9].
  • Second-Generation (Pasireotide): This is used if first-generation drugs don’t work. It is very effective for tumor shrinkage but has a higher risk of raising blood sugar or causing diabetes [11][12].

2. GH-Receptor Antagonist (Pegvisomant)

If SRLs fail, Pegvisomant is a highly effective alternative [1]. Instead of stopping the tumor from making GH, it blocks the GH from working in your body [1]. It normalizes IGF-1 levels in 65% to 97% of patients [1][13].

  • Important Monitoring Detail: Because this drug blocks the receptor instead of stopping the tumor, your blood GH levels will actually remain high or even increase. Do not panic if you see a high GH result on your patient portal; when taking Pegvisomant, doctors only use your IGF-1 levels to measure success [1]. It also requires regular monitoring of your liver enzymes [1].

3. Dopamine Agonists (Cabergoline)

Taken as a pill, Cabergoline is sometimes used alongside other treatments, especially for patients who only have a slight elevation in their hormone levels [14][15].

Third Line: Radiotherapy

Radiation is typically reserved as a “third-line” option when surgery and medications haven’t fully controlled the disease [16][17].

  • Stereotactic Radiosurgery (SRS): This delivers a single, high-precision dose of radiation [18]. It is often preferred for smaller tumors and may lower hormone levels faster than other types of radiation [18][16].
  • Fractionated Radiotherapy (FSRT): This delivers smaller doses of radiation over several weeks [18]. It is sometimes used for larger tumors or those very close to the optic nerves [19].

Be aware that radiation works slowly; it can take several years for your hormone levels to fully reach their targets [20][21]. Your care team will monitor you closely for potential side effects, such as new hormone deficiencies, during this time [20][16].

Read next: Survivorship & Monitoring: Managing Your Long-Term Health

Frequently Asked Questions

What is the first-line treatment for acromegaly?
For most patients, endoscopic transsphenoidal surgery is the primary treatment. A neurosurgeon removes the tumor through the nose and sphenoid sinus, which can often normalize hormone levels without the need for external incisions.
What happens if surgery doesn't cure my acromegaly?
If surgery isn't possible or doesn't completely normalize your hormone levels, doctors usually prescribe medical therapies. The most common first-line medications are Somatostatin Receptor Ligands (SRLs), which tell your body to stop producing excess growth hormone.
Why are my growth hormone levels high while taking Pegvisomant?
Pegvisomant blocks growth hormone from working in your body rather than stopping the tumor from making it. Because of this, your blood growth hormone levels will remain high or even increase, so doctors will monitor your IGF-1 levels instead to measure treatment success.
What are the risks of pituitary surgery for acromegaly?
While generally safe, potential risks include a cerebrospinal fluid (CSF) leak, meningitis, or damage to the normal pituitary gland. Damage to the healthy gland can lead to permanent hormone deficiencies, such as diabetes insipidus, which require lifelong medication.
When is radiation therapy used for acromegaly?
Radiation is typically a third-line option used only when surgery and medications have not fully controlled the disease. It works very slowly, and it can take several years for hormone levels to fully reach their target ranges.

Questions for Your Doctor

  • • How many endoscopic transsphenoidal surgeries have you performed for acromegaly specifically?
  • • If we find that surgery did not achieve full biochemical remission, how long will we wait before starting medical therapy?
  • • Given my current health (such as blood sugar levels), which second-line medication—Pegvisomant or Pasireotide—is a safer choice for me?
  • • If I need radiation, which type (SRS or FSRT) do you recommend for the location and size of my residual tumor?
  • • What are the long-term monitoring steps if I begin combination therapy with two different types of medications?
  • • What are the warning signs of a CSF leak or meningitis after surgery that I should look out for?

Questions for You

  • • Am I comfortable with the idea of surgery, or do I want to discuss primary medical therapy as a first step?
  • • How much does the convenience of the treatment (e.g., daily injections vs. monthly ones) matter to me?
  • • Have I tracked my blood sugar levels recently, especially if my doctor is considering medications that can affect glucose?
  • • Do I have a support system in place for the recovery period after surgery?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Pegvisomant therapy for acromegaly.

    Freda PU

    Expert review of endocrinology & metabolism 2006; (1(4)):489-498 doi:10.1586/17446651.1.4.489.

    PMID: 30290464
  2. 2

    Medical treatment of acromegaly - When the tumor size matters: A narrative review.

    Doknic M, Stojanovic M, Miljic D, Milicevic M

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2024; (78()):101608 doi:10.1016/j.ghir.2024.101608.

    PMID: 39116789
  3. 3

    Comparative effectiveness of endoscopic and microscopic adenoma removal in acromegaly.

    Vassilyeva N, Mena N, Kirov K, Diatlova E

    Frontiers in endocrinology 2023; (14()):1128345 doi:10.3389/fendo.2023.1128345.

    PMID: 37766690
  4. 4

    Endoscopic endonasal transsphenoidal surgery in acromegaly with conchal sphenoid sinus.

    Yamazaki D, Ogiwara T, Hirayama S, et al.

    British journal of neurosurgery 2023; (37(6)):1832-1834 doi:10.1080/02688697.2021.1940851.

    PMID: 34148449
  5. 5

    Transsphenoidal Surgery for Pituitary Tumors and Other Sellar Masses.

    Owen TJ, Martin LG, Chen AV

    The Veterinary clinics of North America. Small animal practice 2018; (48(1)):129-151 doi:10.1016/j.cvsm.2017.08.006.

    PMID: 29056398
  6. 6

    Pituitary surgery's epidemiology using a national inpatient database in Japan.

    Hattori Y, Tahara S, Aso S, et al.

    Acta neurochirurgica 2020; (162(6)):1317-1323 doi:10.1007/s00701-020-04270-4.

    PMID: 32125502
  7. 7

    Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors.

    Babu H, Ortega A, Nuno M, et al.

    Neurosurgery 2017; (81(2)):357-366 doi:10.1093/neuros/nyx020.

    PMID: 28368500
  8. 8

    Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly.

    Kim JH, Hur KY, Lee JH, et al.

    World neurosurgery 2017; (104()):272-278 doi:10.1016/j.wneu.2017.04.141.

    PMID: 28465267
  9. 9

    Treatment of acromegaly with oral octreotide.

    Remba-Shapiro I, Nachtigall LB

    Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101888 doi:10.1016/j.beem.2024.101888.

    PMID: 38443224
  10. 10

    Pasireotide: a novel treatment for patients with acromegaly.

    Cuevas-Ramos D, Fleseriu M

    Drug design, development and therapy 2016; (10()):227-39 doi:10.2147/DDDT.S77999.

    PMID: 26811671
  11. 11

    Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.

    Shimon I, Adnan Z, Gorshtein A, et al.

    Endocrine 2018; (62(2)):448-455 doi:10.1007/s12020-018-1690-5.

    PMID: 30051198
  12. 12

    Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.

    Araujo-Castro M, Biagetti B, Menéndez Torre E, et al.

    Endocrine-related cancer 2024; (31(7)).

    PMID: 38713182
  13. 13

    Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.

    Yamaguchi H, Shimatsu A, Okayama A, Sato T

    Endocrine journal 2020; (67(2)):201-210 doi:10.1507/endocrj.EJ19-0266.

    PMID: 31723069
  14. 14

    Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.

    Mangupli R, Rostomyan L, Castermans E, et al.

    Pituitary 2016; (19(5)):507-14 doi:10.1007/s11102-016-0732-3.

    PMID: 27287035
  15. 15

    PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.

    Ezzat S, Caspar-Bell GM, Chik CL, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(4)):379-393 doi:10.4158/EP-2018-0500.

    PMID: 30657362
  16. 16

    Role of radiotherapy in the management of acromegaly.

    Biermasz NR, Pereira AM, Neelis KJ, et al.

    Expert review of endocrinology & metabolism 2006; (1(3)):449-460 doi:10.1586/17446651.1.3.449.

    PMID: 30764082
  17. 17

    Management of persistent acromegaly following primary therapy: The current landscape in the UK.

    Kyriakakis N, Seejore K, Hanafy A, Murray RD

    Endocrinology, diabetes & metabolism 2020; (3(3)):e00158 doi:10.1002/edm2.158.

    PMID: 32704572
  18. 18

    Comparing Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy in Treating patients with Growth Hormone-Secreting Adenomas: A Systematic Review and Meta-analysis.

    Zheng Q, Huang Y, Lin W, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; doi:10.4158/EP-2020-0110.

    PMID: 32576046
  19. 19

    Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy With a Linear Accelerator (LINAC) for Acromegaly Remission: Clinical Experience From a Tertiary Neurological Center in Latin America.

    Santos-Santos RI, Flores-Vázquez JG, Rodriguez-Hernandez LA, et al.

    Cureus 2025; (17(7)):e88708 doi:10.7759/cureus.88708.

    PMID: 40861590
  20. 20

    Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study.

    Ding D, Mehta GU, Patibandla MR, et al.

    Neurosurgery 2019; (84(3)):717-725 doi:10.1093/neuros/nyy178.

    PMID: 29757421
  21. 21

    Gamma Knife radiosurgery for acromegaly: Evaluating the role of the biological effective dose associated with endocrine remission in a series of 42 consecutive cases.

    Balossier A, Tuleasca C, Cortet-Rudelli C, et al.

    Clinical endocrinology 2021; (94(3)):424-433 doi:10.1111/cen.14346.

    PMID: 32984972

This page provides information on standard acromegaly treatments for educational purposes only. Always consult your endocrinologist and neurosurgeon to determine the safest and most effective treatment plan for your specific condition.

Stay up to date

Get notified when new research about Acromegaly is published.

No spam. Unsubscribe anytime.